Active Foxp3 (+) Regulatory T Cells Rather Than Other Foxp3 (+) T Cells Subsets CorrelateWith Clinical Response To Infliximab Therapy For IBD

Poster (2012, October)

Sequential T2 Relaxometry as a Non-Invasive Assessment of Transmural Inflammation in a Murine Model of Chronically Relapsing Colitis

Poster (2012, May)

Repeated cycles of DSS inducing a chronically relapsing inflammation: A novel model to study fibrosis using in vivo MRI T2 relaxometry

Poster (2012, February)

Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease

in Journal of Crohn’s and Colitis [=JCC] (2011)

Tolerability of shortened infliximab infusion times in patients with inflammatory bowel disease: a single center cohort study

in Acta Gastro-Enterologica Belgica (2011)

Tolerability of shortened infliximab infusion times in patients with inflammatory bowel disease: a single center cohort study

in Gut (2010)

Kinetics of C-Reactive Protein (CRP) following maintenance infliximab treatment in Crohn's disease identifies profiles of patients with better outcome

in Gastroenterology (2010), 138(5 (Suppl I)), -686

Intestinal mucosal expression of matrix metalloproteinase and ADAM genes in patients with inflammatory bowel disease and the impact of infliximab therapy

in Gastroenterology (2010), 138(5), 677

Kinetics of C-reactive Protein (CRP) Following Maintenance Infliximab Treatment in Crohn’s disease identifies profiles of patients with better outcome

in Journal of Crohn’s and Colitis [=JCC] (2010)

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

in Gut (2009), 58(12), 1612-9

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti ... [more ▼]

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two cohorts of patients who received their first treatment with infliximab for refractory ulcerative colitis were studied. Response to infliximab was defined as endoscopic and histological healing. Total RNA from pre-treatment colonic mucosal biopsies was analysed with Affymetrix Human Genome U133 Plus 2.0 Arrays. Quantitative RT-PCR was used to confirm microarray data. RESULTS: For predicting response to infliximab treatment, pre-treatment colonic mucosal expression profiles were compared for responders and non-responders. Comparative analysis identified 179 differentially expressed probe sets in cohort A and 361 in cohort B with an overlap of 74 probe sets, representing 53 known genes, between both analyses. Comparative analysis of both cohorts combined, yielded 212 differentially expressed probe sets. The top five differentially expressed genes in a combined analysis of both cohorts were osteoprotegerin, stanniocalcin-1, prostaglandin-endoperoxide synthase 2, interleukin 13 receptor alpha 2 and interleukin 11. All proteins encoded by these genes are involved in the adaptive immune response. These markers separated responders from non-responders with 95% sensitivity and 85% specificity. CONCLUSION: Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-)response to infliximab. Further study of the pathways involved should allow a better understanding of the mechanisms of resistance to infliximab therapy in ulcerative colitis. ClinicalTrials.gov number, NCT00639821. [less ▲]